Literature DB >> 3492956

The localization of anti-tumour monoclonal antibodies in colorectal cancer.

N C Armitage.   

Abstract

The localization of antitumour monoclonal antibodies was studied in patients with colorectal cancer after intravenous injection. The monoclonal antibody 791T/36 was shown to localise in primary and secondary disease with a preferential uptake of 2.5:1 compared with normal colon. Improved imaging properties were achieved by changing the radiolabel from 131I to 111In and by emission tomography. Using an anti-CEA antibody, C46, a preferential rate of uptake of 5.8:1 was achieved giving superior images and enhancing the prospects of effective targeting of antitumour agents.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3492956      PMCID： PMC2498300     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN： 0035-8843            Impact factor:   1.891


  31 in total

1.  The localization of antilymphosarcoma antibodies in the Murphy lymphosarcoma of the rat.

Authors:  L KORNGOLD; D PRESSMAN
Journal:  Cancer Res       Date:  1954-02       Impact factor: 12.701

2.  Imaging of primary and metastatic colorectal cancer using an 111In-labelled antitumour monoclonal antibody (791T/36).

Authors:  N C Armitage; A C Perkins; M V Pimm; M L Wastie; R W Baldwin; J D Hardcastle
Journal:  Nucl Med Commun       Date:  1985-10       Impact factor: 1.690

3.  The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients.

Authors:  M V Pimm; A C Perkins; N C Armitage; R W Baldwin
Journal:  J Nucl Med       Date:  1985-09       Impact factor: 10.057

4.  Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody.

Authors:  P A Farrands; A C Perkins; M V Pimm; M J Embleton; J D Hardy; R W Baldwin; J D Hardcastle
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

5.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

6.  Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody.

Authors:  R H Begent; P A Keep; A J Green; F Searle; K D Bagshawe; R F Jewkes; B E Jones; G M Barratt; B E Ryman
Journal:  Lancet       Date:  1982-10-02       Impact factor: 79.321

7.  The localization of human breast carcinomas by radiolabelled monoclonal antibodies.

Authors:  R M Rainsbury
Journal:  Br J Surg       Date:  1984-10       Impact factor: 6.939

8.  Radioimmunolocalization and selection for surgery in recurrent colorectal cancer.

Authors:  R H Begent; P A Keep; F Searle; A J Green; H D Mitchell; B E Jones; J Dent; J E Pendower; R A Parkins; K W Reynolds
Journal:  Br J Surg       Date:  1986-01       Impact factor: 6.939

9.  Improved radioimaging and tumor localization with monoclonal F(ab')2.

Authors:  R L Wahl; C W Parker; G W Philpott
Journal:  J Nucl Med       Date:  1983-04       Impact factor: 10.057

10.  Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line.

Authors:  M J Embleton; B Gunn; V S Byers; R W Baldwin
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.